Several clinical trials targeting leukemia and lymphoma have recently begun enrollment. Maybe one of your patients could benefit from participating?
Hematologic malignancies scheduled for human leukocyte antigen-mismatched unrelated donor transplantation. Adult patients under the age of 66 in this situation may be candidates for a randomized, open-label, phase 2 trial conducted by the International Center for Blood and Marrow Transplant Research.
The aim of the study was to find out whether cyclophosphamide, which is given to prevent a dreaded complication of stem cell transplants called graft-versus-host disease, can be safely reduced without increasing infections or reducing protection. It’s about testing whether. All participants will receive cyclophosphamide on day 3 and her day 4 post-transplant. One group will receive a reduced dose of cyclophosphamide (25 mg/kg per dose) and the other group will receive the normal dose (37.5 mg/kg).
Sites in Michigan, Missouri, Oregon, Virginia, and Washington began recruiting 190 participants in December 2023. Learning centers in Florida, Massachusetts, New York and Wisconsin are also planned. Infection-free survival is the primary endpoint, and overall survival is a secondary endpoint. Quality of life (QoL) is not recorded. For more information, visit clinicaltrials.gov.
Untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Adults who are newly diagnosed with this type of cancer and have active disease should test nemtabrutinib (manufactured by Merck Sharp & Dohme), an experimental Bruton’s tyrosine kinase (BTK) inhibitor, against a reference standard. You may want to consider a randomized, open-label, phase 3 trial. The notable BTK inhibitors ibrutinib (Imbruvica) and acalabrutinib (Calquence).
BTK inhibitors target B-cell proliferation in B-cell cancers such as CLL/SLL and enable chemotherapy-free treatment of some hematological malignancies. In this study, participants will take oral nemtabrutinib, ibrutinib, or acalabrutinib daily until disease progression, unacceptable toxicity, or another reason for discontinuation.
The study began in December 2023 with 1,200 participants in Pennsylvania, Washington, Taiwan, Israel, and the United Kingdom. The primary outcomes were objective response rate and progression-free survival. Overall survival is a secondary outcome and QoL is not measured. For more information, visit clinicaltrials.gov.
Relapsed or refractory leukemia Kuomintang 2A-Gene rearrangement (Kuomintang 2A-r). Children between the ages of 1 month and 6 years with this diagnosis will be tested on an open-label basis to determine the most well-tolerated and/or effective dose of the addition of an experimental oral drug called levmenib. You may be eligible to participate in a clinical, non-randomized, pediatric oncology group phase 2 study. chemical treatment.
Kuomintang 2A– Genetic alterations are associated with poor prognosis in leukemia. These changes cause blood cells to dedifferentiate and begin to grow uncontrollably as leukemic cells.Damaged look Kuomintang 2A Genes depend on a protein called menin. Syndax Pharmaceuticals’ Revumenib blocks menin and prevents its expression. Kuomintang 2A.
Children in the study will receive two different regimens of levmenib in combination with chemotherapy for up to one year, or until disease progression or unacceptable toxicity, and will then be followed for up to five years. His trial centers in 12 states in the United States opened in January 2024, with him seeking 78 participants. Toxicity and minimal residual disease are the main outcomes. Overall survival is a secondary outcome and QoL is not assessed. For more information, visit clinicaltrials.gov.
Previously untreated follicular lymphoma or diffuse large B-cell lymphoma. Adults with any of these types of lymphoma may be eligible for one of three open-label, randomized, phase 3 trials testing odronectamab (Regeneron). This bispecific antibody is designed to “bind” CD20 on cancer cells with CD3-expressing cancer cell-killing T cells. Antilymphoma activity has been demonstrated in well-pretreated patients.
In late 2023, three phase 3 trials focused on previously untreated patients and began recruiting 2115 participants to evaluate odronestamab in this setting.trial Olympia-1 Comparing odronectamab with standard treatment rituximab (Rituxan) and chemotherapy in follicular lymphoma. Olympia-2 The drug will also be tested in combination with chemotherapy in follicular lymphoma. Olympia-3 We plan to evaluate odronectamab versus rituximab and chemotherapy in patients with large B-cell lymphoma.
All study drugs, including odronestamab, will be administered intravenously, and participants will be followed for up to five years. Research centers in eight U.S. states and in Australia, the Czech Republic, France, Italy, Poland, Spain, Turkey, and Thailand are currently accepting participants for the three trials. The primary outcomes are toxicity and complete response at 30 months in the follicular lymphoma study and various measures of toxicity and progression-free survival in large B-cell lymphoma. All three trials measured overall survival and QoL as secondary endpoints.
Stage II, III, or IV follicular lymphoma with no prior treatment. Adults with this type of cancer are being tested in a randomized, open-label trial to test whether an experimental treatment called epcolitamab (AbbVie) improves disease response and is well tolerated when added to standard treatment. There is a possibility of participating in a phase III trial. For up to 120 weeks, one group of participants will receive a combination of intravenous rituximab and oral lenalidomide (Revlimid), while the other group will also receive subcutaneous epcolitamab. Some participants may also be offered a choice of chemotherapy by researchers.
Sites in Iowa, Maryland, Missouri, Ohio, Washington, and Montana began accepting 900 participants in February 2024. The primary outcome was complete response at 30 months. Overall survival and QoL were secondary outcomes. For more information, visit clinicaltrials.gov.
Relapsed or refractory mantle cell lymphoma. Adults facing any of these clinical scenarios should be advised by Academic and Community Cancer Research United, which examines the efficacy of the combination of tafasitamab (Monjuvi), lenalidomide, and venetoclax (Venclesta) in such patients. You can participate in the open-label Phase 2 trial.
Front-line treatments do not cure mantle cell lymphoma, and continued recurrence is common. Treatments in this case include acalabrutinib, ibrutinib, stem cell transplant, venetoclax, lenalidomide, and rituximab.
In this study, participants will take venetoclax and lenalidomide daily according to clinic standards and receive intravenous tafasitamab every two weeks after an initial titration period. Participants will be followed for 5 years after joining the study. The Mayo Clinic in Rochester, Minn., has begun recruiting 100 trial participants, scheduled for January 2024. The primary outcome is objective response rate. Overall survival is a secondary outcome and QoL is not tracked. For more information, visit clinicaltrials.gov.
All trial information was obtained from the National Institutes of Health’s U.S. National Library of Medicine (online, clinicaltrials.gov).
